- Home
- ISPR vs CTNM Comparison
ISPR vs CTNM Comparison
Compare ISPR & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ISPR
- CTNM
- Stock Information
- Founded
- ISPR 2019
- CTNM 2009
- Country
- ISPR United States
- CTNM United States
- Employees
- ISPR N/A
- CTNM N/A
- Industry
- ISPR Medicinal Chemicals and Botanical Products
- CTNM
- Sector
- ISPR Health Care
- CTNM
- Exchange
- ISPR Nasdaq
- CTNM Nasdaq
- Market Cap
- ISPR 152.0M
- CTNM 122.9M
- IPO Year
- ISPR 2023
- CTNM 2024
- Fundamental
- Price
- ISPR $2.56
- CTNM $3.83
- Analyst Decision
- ISPR Strong Buy
- CTNM Strong Buy
- Analyst Count
- ISPR 2
- CTNM 4
- Target Price
- ISPR $10.00
- CTNM $22.50
- AVG Volume (30 Days)
- ISPR 75.5K
- CTNM 215.0K
- Earning Date
- ISPR 05-12-2025
- CTNM 08-12-2025
- Dividend Yield
- ISPR N/A
- CTNM N/A
- EPS Growth
- ISPR N/A
- CTNM N/A
- EPS
- ISPR N/A
- CTNM N/A
- Revenue
- ISPR $144,700,345.00
- CTNM N/A
- Revenue This Year
- ISPR N/A
- CTNM N/A
- Revenue Next Year
- ISPR $35.39
- CTNM N/A
- P/E Ratio
- ISPR N/A
- CTNM N/A
- Revenue Growth
- ISPR N/A
- CTNM N/A
- 52 Week Low
- ISPR $2.09
- CTNM $3.35
- 52 Week High
- ISPR $8.13
- CTNM $22.00
- Technical
- Relative Strength Index (RSI)
- ISPR 50.95
- CTNM N/A
- Support Level
- ISPR $2.09
- CTNM N/A
- Resistance Level
- ISPR $2.56
- CTNM N/A
- Average True Range (ATR)
- ISPR 0.22
- CTNM 0.00
- MACD
- ISPR 0.00
- CTNM 0.00
- Stochastic Oscillator
- ISPR 61.84
- CTNM 0.00
About ISPR Ispire Technology Inc.
Ispire Technology Inc is engaged in the research and development, design, commercialization, sales, marketing, and distribution of branded e-cigarettes and cannabis vaping products. The company sells its cannabis vaping in the United States, Europe, Canada, and South Africa.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.